{"title":"Atypical aging in down syndrome","authors":"Warren B. Zigman","doi":"10.1002/ddrr.1128","DOIUrl":null,"url":null,"abstract":"<p>At present, there may be over 210,000 people with Down syndrome (DS) over the age of 55 in the United States (US) who have significant needs for augmented services due to circumstances related to ordinary and/or pathological aging. From 1979 through 2003, the birth prevalence of DS rose from 9.0 to 11.8 (31.1%) per 10,000 live births in 10 representative US regions. This increase, largely due to women conceiving after age 35, portends an ever-growing population of people with DS who may be subject to pathogenic aging. Whereas Trisomy 21 is one of the most widespread genetic causes of intellectual disability (ID), it still is one of the least understood of all genetic ID syndromes. While longevity in people with DS has improved appreciably in as modest a period as 30 years, age-specific risk for mortality still is considerably increased compared both with other people with ID or with the typically developing population. The penetrance of the phenotype is widely distributed, even though a consistent genotype is assumed in 95% of the cases. Some, but not all body systems, exhibit signs of premature or accelerated aging. This may be due to both genetic and epigenetic inheritance. We now know that the long-term outcome for people with DS is not as ominous as once contemplated; a number of people with DS are living into their late 60s and 70s with few if any major signs of pathogenic aging. Alzheimer's disease (AD), a devastating disease that robs a person of their memory, abilities and personality, is particularly common in elder adults with DS, but is not a certainty as originally thought, some 20% to 30% of elder adults with DS might never show any, or at most mild signs of AD. DS has been called a mature well-understood syndrome, not in need of further research or science funding. We are only beginning to understand how epigenetics affects the phenotype and it may be feasible in the future to alter the phenotype through epigenetic interventions. This chapter is divided into two sections. The first section will review typical and atypical aging patterns in somatic issues in elder adults with DS; the second section will review the multifaceted relationship between AD and DS. © 2013 Wiley Periodicals, Inc. Dev Disabil Res Rev 2013;18:51–67.</p>","PeriodicalId":55176,"journal":{"name":"Developmental Disabilities Research Reviews","volume":"18 1","pages":"51-67"},"PeriodicalIF":0.0000,"publicationDate":"2013-08-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/ddrr.1128","citationCount":"226","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Developmental Disabilities Research Reviews","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/ddrr.1128","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 226
Abstract
At present, there may be over 210,000 people with Down syndrome (DS) over the age of 55 in the United States (US) who have significant needs for augmented services due to circumstances related to ordinary and/or pathological aging. From 1979 through 2003, the birth prevalence of DS rose from 9.0 to 11.8 (31.1%) per 10,000 live births in 10 representative US regions. This increase, largely due to women conceiving after age 35, portends an ever-growing population of people with DS who may be subject to pathogenic aging. Whereas Trisomy 21 is one of the most widespread genetic causes of intellectual disability (ID), it still is one of the least understood of all genetic ID syndromes. While longevity in people with DS has improved appreciably in as modest a period as 30 years, age-specific risk for mortality still is considerably increased compared both with other people with ID or with the typically developing population. The penetrance of the phenotype is widely distributed, even though a consistent genotype is assumed in 95% of the cases. Some, but not all body systems, exhibit signs of premature or accelerated aging. This may be due to both genetic and epigenetic inheritance. We now know that the long-term outcome for people with DS is not as ominous as once contemplated; a number of people with DS are living into their late 60s and 70s with few if any major signs of pathogenic aging. Alzheimer's disease (AD), a devastating disease that robs a person of their memory, abilities and personality, is particularly common in elder adults with DS, but is not a certainty as originally thought, some 20% to 30% of elder adults with DS might never show any, or at most mild signs of AD. DS has been called a mature well-understood syndrome, not in need of further research or science funding. We are only beginning to understand how epigenetics affects the phenotype and it may be feasible in the future to alter the phenotype through epigenetic interventions. This chapter is divided into two sections. The first section will review typical and atypical aging patterns in somatic issues in elder adults with DS; the second section will review the multifaceted relationship between AD and DS. © 2013 Wiley Periodicals, Inc. Dev Disabil Res Rev 2013;18:51–67.
唐氏综合症的非典型衰老
目前,美国55岁以上的唐氏综合症(DS)患者可能超过21万人,他们由于正常和/或病理性衰老的相关情况而对增强服务有重大需求。从1979年到2003年,在美国10个代表性地区,DS的出生患病率从每10,000名活产婴儿中9.0人上升到11.8人(31.1%)。这一增长,主要是由于35岁以后怀孕的妇女,预示着越来越多的患有退行性痴呆的人可能会受到致病性衰老的影响。虽然21三体是智力残疾(ID)最普遍的遗传原因之一,但它仍然是所有遗传ID综合征中最不为人所知的。虽然退行性痴呆患者的寿命在30年的时间内有了明显的改善,但与其他退行性痴呆患者或典型发展人群相比,年龄特异性死亡风险仍然大大增加。尽管在95%的病例中假设基因型一致,但表型的外显率分布广泛。一些,但不是所有的身体系统,表现出过早或加速衰老的迹象。这可能是由于遗传和表观遗传。我们现在知道,退行性痴呆患者的长期结局并不像以前想象的那样不祥;许多退行性痴呆患者活到60多岁和70多岁,几乎没有任何主要的致病性衰老迹象。阿尔茨海默病(AD)是一种使人丧失记忆、能力和个性的毁灭性疾病,在老年退行性痴呆患者中尤为常见,但并不像最初认为的那样确定,大约20%至30%的老年退行性痴呆患者可能永远不会表现出任何症状,或最多表现出轻微的AD症状。退行性椎体滑移症被称为一种成熟的、众所周知的综合征,不需要进一步的研究或科学资助。我们才刚刚开始了解表观遗传是如何影响表型的,未来通过表观遗传干预来改变表型可能是可行的。本章分为两节。第一部分将回顾典型和非典型衰老模式在老年退行性痴呆的躯体问题;第二部分将回顾AD和DS之间的多方面关系。©2013 Wiley期刊公司发展与残疾,2013;18:51-67。
本文章由计算机程序翻译,如有差异,请以英文原文为准。